Results 41 to 50 of about 4,626,170 (385)
Therapeutic Advances in Medical Oncology, 2020 Objective: Neoadjuvant chemotherapy has increased the survival benefit of non-small cell lung cancer (NSCLC) patients. The effects of different neoadjuvant therapies are still controversial. We carried out the study to evaluate the efficacy and safety of
Yijiu Ren +6 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Background: Significant survival benefit of adjuvant imatinib therapy has been observed in gastrointestinal stromal tumor (GIST). However, the impact of neoadjuvant imatinib on prognosis of GIST remains unclear.
Zhen Liu +8 more
doaj +1 more source
Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer
Frontiers in Immunology, 2022 Pancreatic cancer has an exclusive inhibitory tumor microenvironment characterized by a dense mechanical barrier, profound infiltration of immunosuppressive cells, and a lack of penetration of effector T cells, which constitute an important cause for ...
Huiru Zhang +4 more
semanticscholar +1 more source
Immunonutrition before esophagectomy: Impact on immune surveillance mechanisms [PDF]
, 2017 Preoperative oral immunonutrition was demonstrated to improve immune response and to decrease the infection rate in patients with cancer. This study aimed to assess how immunonutrition could influence the immune cell response in the mucosal ...
Agostini, Marco +12 more
core +1 more source
npj Breast Cancer, 2021 Neoadjuvant therapy in breast cancer can downstage axillary lymph nodes and reduce extent of axillary surgery. As such, accurate determination of nodal status after neoadjuvant therapy and before surgery impacts surgical management. There are scarce data
Mary Kathryn Abel +11 more
doaj +1 more source
Neoadjuvant therapy induces a potent immune response to sarcoma, dominated by myeloid and B cells.
Clinical Cancer Research, 2022 PURPOSE To characterize changes in the soft tissue sarcoma tumor immune microenvironment induced by standard neoadjuvant therapy with the goal of informing neoadjuvant immunotherapy trial design.
P. Goff +28 more
semanticscholar +1 more source
Frontiers in Oncology, 2021 BackgroundImmune checkpoint inhibitors (ICIs) have shown promising anti-tumor activity in multiple malignances including breast cancer. However, the responses can vary.
Yunhai Li +10 more
doaj +1 more source
The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients [PDF]
, 2018 Background: Preoperative chemoradiotherapy (CRT) followed by surgery is the standard care for locally advanced rectal cancer, but tumour response to CRT and disease outcome are variable.
A Celeghin +62 more
core +1 more source
Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report
Heliyon, 2023 Purpose: Platinum-based regimens are regarded as the preferred alternative for neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC) patients. However, some patients cannot tolerate platinum-based regimens. We report an MIBC case with severe
Haijun Huang +5 more
doaj
Zurich Consensus: Statement of German Experts on St. Gallen Conference 2011 on Primary Breast Cancer (Zurich 2011) [PDF]
, 2011 Every 2 years, the International Consensus Conference on the Treatment of Primary Breast Cancer takes place in St. Gallen. Given that the concept of the St.
Beckmann, Matthias W. +27 more
core +1 more source